RxDoctor Payments DataLook up a doctor →

Marcel Zughaib, MD

Interventional Cardiology · Southfield, MINPI 1922038488

Payments from drug & device makers

$1,218,333in general payments, 2019–2025

Across 596 payments — averaging $2044.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$553K
  • Merck$259K
  • Novartis$175K
  • Johnson & Johnson$173K
  • Medtronic$21K
  • Sanofi-aventis U.S. LLC$12K
  • plus $24K from 43 others

What the payments were for

  • Royalty or licence$19,1577%
  • Consulting fees$7,9163%
  • Speaking & faculty fees$195,39576%
  • Travel & lodging$11,7875%
  • Food & beverage$22,1459%
  • Education$120%
  • Entertainment$1430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,218,333 in reported general payments places this provider in the 95th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$176,825
Medicare patients
746
Services billed
2,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban399$532,481
EliquisApixaban125$133,922
EntrestoSacubitril/Valsartan69$99,579
Repatha SureclickEvolocumab55$48,832
FarxigaDapagliflozin Propanediol22$30,928
JardianceEmpagliflozin18$26,099
Praluent PenAlirocumab28$19,296
Atorvastatin Calcium943$13,082
Carvedilol950$12,221
Ranolazine ErRanolazine100$10,672
Losartan Potassium547$6,916
ClopidogrelClopidogrel Bisulfate342$6,419
Ezetimibe282$6,223
Metoprolol Succinate299$5,324
Lisinopril445$4,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$173,332$532,481399 claims
PfizerEliquis$79$133,922125 claims
NovartisEntresto$175,024$99,57969 claims
AstraZenecaFarxiga$69$30,92822 claims
Boehringer IngelheimJardiance$325$26,09918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →